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Abstract: Four monomethoxy poly(ethylene glycol)-poly(L-lactide-co-glycolide)2 (mPEG-
P(LA-co-GA)2) copolymers were synthesized by ring-opening polymerization of L-lactide and 
glycolide with double hydroxyl functionalized mPEG (mPEG-(OH)2) as macroinitiator and 
stannous octoate as catalyst. The copolymers self-assembled into nanoscale micellar/vesicular 
  aggregations in phosphate buffer at pH 7.4. Doxorubicin (DOX), an anthracycline anticancer 
drug, was loaded into the micellar/vesicular nanoparticles, yielding micellar/vesicular nanomedi-
cines. The in vitro release behaviors could be adjusted by content of hydrophobic polyester and 
pH of the release medium. In vitro cell experiments showed that the intracellular DOX release 
could be adjusted by content of P(LA-co-GA), and the nanomedicines displayed effective 
proliferation inhibition against Henrietta Lacks’s cells with different culture times. Hemolysis 
tests indicated that the copolymers were hemocompatible, and the presence of copolymers could 
reduce the hemolysis ratio of DOX significantly. These results suggested that the novel anticancer 
nanomedicines based on DOX and amphiphilic Y-shaped copolymers were   attractive candidates 
as tumor tissular and intracellular targeting drug delivery systems in vivo, with enhanced stabil-
ity during circulation and accelerated drug release at the target sites.
Keywords: amphiphilic Y-shaped copolymer, anticancer nanomedicine, cellular proliferation 
inhibition, doxorubicin
Introduction
Over the past decade, a new era in nanosized polymer-based pharmaceuticals has 
emerged, via interface of chemistry and biomedical science, to improve the efficacy 
of cancer chemotherapy.1,2 Amphiphilic copolymers have been widely studied as 
economic and versatile nanoscale drug carriers, due to their typical diameter of several 
tens of nanometers and relatively narrow size distribution.3–5 The unique compositions, 
molecular geometry, and physicochemical properties of the amphiphilic copolymers 
enable them to aggregate into nanoparticles with various morphologies in aqueous 
medium, such as micelles6–9 and vesicles.10–12 The nanomedicines based on the above-
mentioned polymeric micellar/vesicular nanoparticles can effectively resist rapid renal 
clearance and nonspecific uptake by the reticuloendothelial system (RES). In addition, 
the nanoparticles can deliver anticancer drugs and genetic agents into target patho-
logical sites, due to the enhanced permeability and retention (EPR) effect in tumor 
vasculature, which improve the efficacy of chemotherapy and reduce the side effects 
of the loaded drug to healthy tissues.4,13–16
Previous studies on micellar/vesicular nanovehicles for anticancer drug delivery 
have focused mainly on the synthesis and self-assembly of linear amphiphilic 
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di/triblock copolymers. Traditional linear amphiphilic block 
copolymers have been able to self-assemble into stabile 
nanoparticles as drug carriers in aqueous solution. However, 
their low drug-loading efficiency and uncontrollable 
degradation have limited their usage in drug delivery.17 
As such, more attention has been paid to amphiphilic 
miktoarm star-shaped copolymers with two or more types 
of chemically different arms, as they might completely 
or partially overcome the problem of thermodynamic 
instability associated with micelles assembled from linear 
amphiphilic di/triblock copolymers.13,18–20 Due to their 
particular molecular architecture, star-shaped copolymers 
are expected to exhibit different properties compared with 
their linear counterparts. For instance, amphiphilic star-
shaped copolymers are superior in host–guest interactions 
and drug delivery compared to conventional linear ones.21–25 
Typically, several synthetic strategies, such as atom transfer 
or nitroxide-mediated radical polymerization (ATRP or 
NMP),26 reversible addition fragmentation chain transfer 
(RAFT), ring-opening polymerization (ROP),27 and “click 
chemistry” reactions,28 have been successfully employed 
in the preparation of star-shaped copolymers with well-
defined macromolecular building blocks and architecture. 
However, the undegradability of the resultant polymer has 
restricted the development of the ATRP, NMP, and RAFT 
methods; the biodegradable blocks can be introduced through 
ROP. Aliphatic polyesters, such as poly(ε-caprolactone) (PCL), 
poly(L-lactide) (PLA), and poly(L-lactide-co-glycolide) 
(PLGA),29 are the most common hydrophobic moieties that 
act as bioactive molecule reservoirs, due to their excellent 
biocompatibility and biodegradability. For biomedical 
applications, however, the hydrophilic segments are 
composed of zwitterionic material or polyethylene glycol 
(PEG), which can resist nonspecific protein adsorption 
(ie, nonfouling properties) and prolong the circulation of 
nanoparticles in the complicated in vivo environment.
Herein, novel amphiphilic Y-shaped copolymers, 
a common type of star-shaped copolymers, composed of 
P(LA-co-GA) and PEG, were designed and synthesized. 
In detail, a series of amphiphilic Y-shaped monomethoxy 
poly(ethylene glycol)-poly(L-lactide-co-glycolide)2 (mPEG-
P(LA-co-GA)2) copolymers were synthesized by ROP of 
L-lactide and glycolide, with mPEG-(OH)2 as macroinitiator 
and stannous octoate (Sn(Oct)2) as catalyst. The obtained 
copolymers formed into micellar/vesicular nanoparticles by 
altering the length of the hydrophobic P(LA-co-GA) block 
in phosphate buffer (PB) at pH 7.4. DOX, a model antican-
cer drug, could be loaded into the cores of nanoparticles, 
yielding micellar/vesicular nanomedicines. In vitro DOX 
release from the nanomedicines in PB was found to be 
accelerated by the decrease of polyester content or in tumor 
tissular and intracellular acidic conditions. The biocompat-
ibilities and hemocompatibilities of the copolymers, and 
the cellular proliferation inhibition of the nanomedicines 
were also investigated. These properties indicated that the 
amphiphilic Y-shaped copolymers are promising materials 
for designing and fabricating DOX-based nanomedicines 
for efficient cancer treatment.
Materials and methods
Materials
Monomethoxy poly(ethylene glycol) (mPEG113, Mn = 5000) 
was purchased from Sigma-Aldrich (St Louis, MO) without 
further purification. Dowex 50W-X2 ion exchange resin 
was obtained from Sigma-Aldrich and used after a simple 
methanol rinse. Stannous octoate (Sn(Oct)2) (.95%, 
Sigma-Aldrich), 2,2-dimethoxypropane (DMP; Sinopharm 
Chemical Reagent Co, Ltd), 2,2-bis(hydroxymethyl) 
propionic acid (BHPA; Sinopharm Chemical Reagent 
Co, Ltd), and 4-dimethylaminopyridine (DMAP) (GL; 
Biochem Co, Ltd) were used as obtained. Acetonide-2,2-
bis(hydroxymethyl) propionic anhydride (ABHPA) was 
prepared from DMP and BHPA according to the procedure 
outlined in the literature.30 L-Lactide and glycolide were 
recrystallized with ethyl acetate before use. Doxorubicin 
hydrochloride (DOX⋅HCl) was purchased from Zhejiang 
Hisun Pharmaceutical Co, Ltd and used as obtained. Toluene 
was stored over calcium hydride (CaH2) and purified by 
vacuum distillation. All the other reagents and solvents were 
purchased from Sinopharm Chemical Reagent Co, Ltd and 
used without further purification.
Synthesis of double hydroxyl 
functionalized mPEG (mPEG-(OH)2)
mPEG-(OH)2 was synthesized by esterification of mPEG 
with ABHPA, using DMAP as a catalyst and the subsequent 
deprotection of acetonide groups, as depicted in Figure 1. 
Briefly, mPEG (10 g, 2 mmol), ABHPA (2.05 g, 6.1 mmol), 
and DMAP (0.23 g, 1.82 mmol) were dissolved in 60 mL 
of a methylene chloride (CH2Cl2)/pyridine (9/1, v/v) mixed 
solvent and stirred overnight at 25°C. Then, 10 mL of 
methanol was added to the mixture and allowed to stir for 
5 hours to quench the excess ABHPA. Finally, the product was 
precipitated in excessive diethyl ether. The obtained product 
was further washed, twice, with diethyl ether, and dried under 
vacuum at room temperature for 24 hours (yield: 97%). 
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1H NMR (400 MHz, CDCl3, ppm): 1.22 (s, 3H, –CH3), 1.43 
(s, 6H, –OC((CH3)2)O–), 3.39 (s, 3H, –OCH3), 3.40–3.91 
(4H, –OCH2CH2O–), 4.19–4.30 (m, 6H, –CH2CH2OC(O)–, 
–OCH2C(C(O))(CH3)CH2O–). Subsequently, the resultant 
product was dissolved in 150 mL of methanol, and then 3.0 g 
of Dowex 50 W-X2 was added to the solution. After stirring 
for 5 hours at 55°C, the Dowex 50 W-X2 was filtered out, and 
the remaining filtrate was precipitated in diethyl ether. The 
precipitate was collected and dried under vacuum to constant 
weight, at room temperature. The yield was approximately 
98%. 1H NMR (400 MHz, CDCl3, ppm): 1.12 (s, 3H, –CH3), 
3.38 (s, 3H, –OCH3), 3.40–3.92 (4H, –OCH2CH2O–), 4.35 
(t, 2H, –CH2CH2OC(O)–).
Synthesis of amphiphilic Y-shaped 
copolymers (mPEG-P(LA-co-GA)2)
Various mPEG-P(LA-co-GA)2 copolymers with different 
compositions (various LA/GA molar ratios) were easily 
prepared by the ROP of L-lactide and glycolide in the pres-
ence of mPEG-(OH)2 as macroinitiator and Sn(Oct)2 as 
catalyst (Figure 1). In brief, mPEG-(OH)2 was dissolved 
in freshly distilled toluene and azeotropically distilled at 
120°C to remove micro-amounts of water. Then, L-lactide, 
glycolide, Sn(Oct)2, and additional toluene were added. The 
mixture was stirred for 24 hours at 120°C under nitrogen. 
The product was precipitated in diethyl ether. The precipitate 
was collected and dried under vacuum to constant weight at 
room temperature (yield: 80–85%).
Preparation of mPEG-P(LA-co-GA)2 
nanoparticles
mPEG-P(LA-co-GA)2 (10.0 mg) was dissolved in 2 mL 
of tetrahydrofuran (THF), and then stirred at room tem-
perature for 2 hours. Subsequently, 1 mL of deionized water 
was added dropwise to the solution, under gentle stirring. 
After stirring for 2 hours at room temperature, the THF was 
removed by dialysis against deionized water for 24 hours to 
obtain the solution of nanoparticles.
Characterization
Proton nuclear magnetic resonance (1H NMR) spectra 
were recorded on a Bruker AV 400 NMR spectrom-
eter in chloroform-d (CDCl3). Fourier transform infrared 
(FT-IR) spectra were recorded on a Bio-Rad Win-IR 
instrument using the potassium bromide (KBr) method. 
Number- and weight-average molecular weights (Mn, Mw) 
and molecular weight distributions (polydispersity index, 
PDI = Mw/Mn) were determined by gel permeation chroma-
tography (GPC), using a series of linear Styragel columns 
(HT3 and HT4) and a Waters 515 HPLC pump, with an 
OPTILAB DSP Interferometric Refractometer (Wyatt Tech-
nology) as   detector. The eluent was chloroform at a flow rate 
of 1.0 mL min−1 at 40°C. The monodispersed polystyrene 
standards with a molecular weight range from 1,310 to 55,100 
were purchased from Waters Co, Ltd, and used to generate the 
calibration curve. Dynamic laser scattering (DLS) measure-
ments were carried out on a WyattQELS instrument with a 
vertically polarized He-Ne laser (DAWN EOS, Wyatt Technol-
ogy). The scattering angle was fixed at 90°. The morphologies 
of the mPEG-P(LA-co-GA)2 nanoparticles were confirmed by 
using transmission electron microscopy (TEM) measurement 
on a JEOL JEM-1011 transmission electron microscope with 
an accelerating voltage of 100 KV . A drop of the nanoparticle 
solution (0.5 g L−1) was deposited onto a 230-mesh copper 
grid coated with carbon, and laid to dry in air at 25°C before 
measuring. The critical aggregation concentration (CAC) was 
determined by fluorescence spectroscopy, using pyrene as the 
fluorescence probe on a PTI Fluorescence Master System with 
Felix 4.1.0 software (λem = 390 nm). The CAC was obtained 
from the intersection of the tangent to the horizontal line of 
O O O
m
O
O
O
O O
O
O
H
O
O
O
O
H x y
y n
n
x
Dowex 50W-X2
O O O
m
O
OH
OH
55°C, 5h
O
O
O
O
O
O
O
O
Sn(Oct)2,1 20°C, 24 h
O O OH
m + O O
O
O
O O
DMAP
CH2Cl2/pyridine( 9/1, v/v) O O O
m
O
O
O
O
+
Figure 1 Synthesis pathway of Y-shaped mPEG-P(LA-co-GA)2 copolymers.
Abbreviations: DMAP, 4-dimethylaminopyridine; Sn(Oct)2, stannous octoate; mPEG, monomethoxy poly(ethylene glycol); P(LA-co-GA), poly(L-lactide-co-glycolide).
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I336.5/I334, with relative constant values and the diagonal line, 
with rapidly increased I336.5/I334 ratio.
Fabrication of nanomedicine and in vitro 
DOX release
The nanomedicines were prepared by the solvent- 
displacement (nanoprecipitation) method (Figure 2). 
Briefly, mPEG-P(LA-co-GA)2 (50.0 mg), DOX ⋅ HCl 
(10.0 mg), and triethylamine (1.8 mg) were dissolved in 
3.0 mL of THF and stirred at room temperature for 5 hours. 
Then, 1 mL of deionized water was added dropwise to this 
solution under stirring. The mixture was stirred at room 
temperature for 6 hours, and then the solution was dialyzed 
against deionized water for 24 hours, using a dialysis bag 
(MWCO 3500 Da), to eliminate THF and excess DOX. 
The solution was filtered and lyophilized to obtain the 
nanomedicine. The drug-loading content (DLC) and drug-
loading efficiency (DLE) of the nanomedicine were calcu-
lated by the following equations: DLC (wt %) = (amount of 
drug in nanomedicine/amount of nanomedicine) × 100, DLE 
(wt %) = (amount of drug in nanomedicine/total amount of 
feeding drug) × 100.
In vitro DOX release behaviors from the nanomedicines 
were investigated in PB at pH 5.3, 6.8, and 7.4. The weighed 
freeze-dried nanomedicine was suspended in 2 mL of PB 
and introduced into a dialysis bag (MWCO 3500 Da). The 
release experiment was initiated by placing the end-sealed 
dialysis bag into 50 mL of PB at 37°C, with continuous 
shaking, at 75 rpm. At given times, 2 mL of external release 
medium was taken out, and the volume withdrawn was 
replenished with an equal volume of fresh release medium. 
The amount of released drug was tested by UV-vis spectro-
photometry at 480 nm, using the standard curve method.
Intracellular DOX release
The intracellular release behaviors of the nanomedicines were 
monitored via confocal laser scanning microscopy (CLSM) 
against Henrietta Lack’s (HeLa) cells (a human cervical 
  carcinoma cell line). The cells were seeded in 6-well culture 
plates at ∼200,000 cells in 2 mL of complete Dulbecco’s 
modified Eagle’s medium (DMEM) per well and cultured 
for 24 hours. Then, the culture medium was removed and 
nanomedicines were added at a final DOX concentration of 
10 mg L−1 (in 2 mL of complete DMEM medium). Free DOX 
was used as control. The cells were incubated with nanomedi-
cines or free DOX for 2 hours. Afterwards, the culture media 
were removed and the cells were washed four times with PB 
and fixed with 4% formaldehyde for 30 minutes at room tem-
perature, and the cell nuclei were dyed with 4′,6-diamidino-
2-phenylindole (DAPI, blue). CLSM images of the cells were 
obtained with a confocal microscope (Olympus FluoView 1000).
Cytotoxicity assay
The cytotoxicities of the nanoparticles and nanomedicines were 
analyzed using methyl thiazolyl tetrazolium (MTT) viability 
assays toward HeLa cells. The cells were seeded in 96-well 
culture plates at a density of 7000 cells per well in 200 µL of 
DMEM containing 10% fetal bovine serum, supplemented with 
50 U mL−1 penicillin and 50 U mL−1 streptomycin, and incu-
bated at 37°C in 5% CO2 atmosphere for 24 hours. Then, the 
culture medium was removed and nanoparticles (0–100 mg L−1) 
or nanomedicines (0–10 mg L−1 DOX) were added to 200 µL 
of complete DMEM medium. The cells were subjected to 
MTT assay after being incubated for three time intervals (24, 
48, and 72 hours), at 37°C, in 5% CO2 atmosphere. The absor-
bance of the medium was measured at 490 nm on a Bio-Rad 
680 microplate reader. Cell viability was calculated based on the 
following equation: Cell viability (%) = (Asample/Acontrol) × 100, 
where Asample and Acontrol are denoted as absorbencies of the 
sample and control wells, respectively.
Hemolysis assay
Hemolytic activities of the nanoparticles and nanomedicines 
were assessed, using spectrophotometry, by monitoring the 
release of hemoglobin from rabbit blood. Potassium oxalate-
stabilized rabbit blood samples were freshly obtained from the 
Micellar nanomedicine
Amphiphilic
Y-shaped copolymers
PB (pH 7.4) PB (pH 7.4)
-P(LA-co-GA)2
Vesicular nanomedicine
DOX mPEG
Figure 2 Schematic illustration of preparation of micellar/vesicular nanomedicines based on DOX and amphiphilic Y-shaped copolymers.
Abbreviations: DOX, doxorubicin; mPEG, monomethoxy poly(ethylene glycol); P(LA-co-GA), poly(L-lactide-co-glycolide); PB, phosphate buffer.
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  Experimental Animal Center of Jilin University. First, 5 mL 
of blood sample was diluted in 30 mL of physiological saline; 
then, red blood cells (RBCs) were isolated from the serum by 
centrifugation at 1200 rpm for 10 minutes. The supernatant 
was carefully removed. The RBCs were further washed five 
times with 30 mL of physiological saline. The purified blood 
was diluted in 15 mL of physiological saline. Then, 0.4 mL 
of diluted RBC suspension was added to 0.4 mL solutions 
of nanoparticles and nanomedicines, at systematically varied 
concentrations, and mixed by vortexing. Physiological saline (−) 
and Triton X-100 (10 g L−1) (+) were used as negative and posi-
tive controls, respectively. All the sample tubes were kept under 
static conditions at 37°C for 1 hour. Finally, the mixtures were 
centrifuged at 3000 rpm for 10 minutes, and 100 µL of super-
natants from all the samples were transferred to a 96-well plate. 
The absorbance values of the supernatants at 540 nm were deter-
mined by a   Bio-Rad 680 microplate reader. The hemolysis ratio 
(HR) of the RBCs was calculated using the following formula:   
hemolysis (%) = (Asample − Anegative control)/(Apositive control − Anegative control) ×   
100, where Asample, Anegitive control and Apositive control are denoted as 
absorbencies of the sample, and negative and positive controls, 
respectively. All hemolysis experiments were carried out in 
triplicate.
Statistical analysis
All the experiments were repeated at least three times. Data 
were expressed as mean ± standard deviation (SD). All results 
were analyzed with a two-tailed Student’s t-test. A value of 
P , 0.05 was considered statistically significant.
Results and discussion
Synthesis and characterization  
of mPEG-P(LA-co-GA)2
The aliphatic polyesters can be directly synthesized by ROP 
of lactone monomers, using covalent metal alkoxides or 
carboxylates (eg, aluminum isopropoxide and Sn(Oct)2) as 
catalysts.31,32 In this work, four types of amphiphilic mPEG-
P(LA-co-GA)2 copolymers, with different contents of P(LA-
co-GA), were synthesized by ROP of L-lactide and glycolide, 
with mPEG-(OH)2 as macroinitiator and Sn(Oct)2 as catalyst. 
As shown in Figure 1 and Table 1, the polymerization was 
conducted in toluene at 120°C, with -OH/LA/GA monomer 
feed molar ratios of 1/7/10, 1/15/10, 1/30/10, and 1/60/20. 
The chemical structures of mPEG-P(LA-co-GA)2 were 
confirmed by 1H NMR and FT-IR spectra (Figure 3). The 1H 
NMR spectra verified the successful synthesis of mPEG-
P(LA-co-GA)2, and all signals were well assigned, as shown 
in Figure 3A. The degrees of polymerization (DP, Table 1) of 
two monomers (LA and GA) in the resultant mPEG-P(LA-
co-GA)2 were calculated by comparing the integrated area of 
peak at (a) 5.17 ppm attributed to methylene proton of the LA 
group and (b) 4.83 ppm assigned to the methylene proton of 
the GA group, with the signal at (e) 3.65 ppm of methylene 
proton of mPEG. The molar compositions of the LA/GA 
monomers in the resultant copolymers were calculated to be 
4/9, 12/9, 24/8, and 45/15. The result of FT-IR (Figure 3B) 
also demonstrated the generation of P(LA-co-GA) block, 
based on the increased strength of carbonyl absorption at 
1759 cm−1 (υC=O), attributed to the ester bond.
The successful synthesis of Y-shaped copolymers 
was further confirmed by the GPC analyses, as shown in 
Figure 4. The unimodal peaks with decreased retention time, 
corresponding to higher molecular weights, demonstrated 
the formation of Y-shaped copolymers. The PDI values of 
the copolymers were around 1.21–1.34. The relatively low 
molecular weight distribution may be explained by the living 
character of the ROP of the GA and LA monomers catalyzed 
by Sn(Oct)2. It should be noted that the Mn measured by GPC 
was relatively higher than that measured by 1H NMR, due to 
the structural difference between the resultant copolymers 
and the monodispersed polystyrene standards that were used 
to generate the calibration curve in GPC analyses.12,33
Self-assembly behavior of mPEG-P 
(LA-co-GA)2
Amphiphilic copolymers are an interesting type of materials 
that can self-assemble into various morphologies in selec-
tive solvents. In this study, Y-shaped mPEG-P(LA-co-GA)2 
Table 1 Characterizations of mPEGP-(LA-co-GA)2 copolymers
Copolymers Feed molar ratioa Resultant molar ratiob Mn (g mol-1)c Mn (g mol-1)d PDId
mPEG113-P(LA4-co-GA9)2 1/7/10 1/4/9 6700 8600 1.21
mPEG113-P(LA12-co-GA9)2 1/15/10 1/12/9 7900 12000 1.22
mPEG113-P(LA24-co-GA8)2 1/30/10 1/24/8 9500 14000 1.28
mPEG113-P(LA45-co-GA15)2 1/60/20 1/45/15 13300 19600 1.34
Notes: aFeed molar ratio of -OH/LA/GA; bresultant molar ratio of –OH/LA/GA, and determined by 1H NMr; cDetermined by 1H NMr; dDetermined by GPC.
Abbreviations: mPEG, monomethoxy poly(ethylene glycol); P(LA-co-GA), poly(L-lactide-co-glycolide); Mn, number-average molecular weight; PDI, polydispersity index; 
LA, L-lactide; GA, glycolide; 1H NMr, proton nuclear magnetic resonance; GPC, gel permeation chromatography.
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copolymers were dissolved in THF, and the solution was 
mixed with water to induce microphase separation of the 
mPEG and P(LA-co-GA) blocks, followed by removing 
THF through dialysis. To demonstrate the formation of self-
assembled aggregates, the widely reported pyrene-probe-
based fluorescence technique was used.34 The fluorescence 
excitation spectra of pyrene in PB solution of mPEG-P(LA12-
co-GA9)2 at different concentrations are shown in Figure 5A. 
It was obvious that fluorescence intensity increased as the 
copolymer concentration increased, due to the transfer 
of pyrene into a hydrophobic environment. A red shift of 
(0, 0) absorption band from 334.5 to 336 nm was observed 
when the copolymer concentration was increased from 
6.10 × 10−5 to 1.25 × 10−1 g L−1. This red shift resulted from 
the transfer of pyrene molecules from a water environment 
to the hydrophobic core, and thus provided information 
on the location of the pyrene probe in the system, in fact, 
indicating the formation of aggregations.13 The critical 
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Elution time (min)
abce d
Figure  4  GPC  chromatograms  of  (a)  mPEG-(OH)2,  (b)  mPEG-P(LA4-co-GA9)2, 
(c) mPEG-P(LA12-co-GA9)2, (d) mPEG-P(LA24-co-GA8)2, and (e) mPEG-P(LA45-co-GA15)2.
Abbreviations:  GPC,  gel  permeation  chromatography;  mPEG,  monomethoxy 
poly(ethylene glycol); P(LA-co-GA), poly(L-lactide-co-glycolide); Mn, number-average 
molecular weight; PDI, polydispersity index.
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aggregation concentration (CAC) was obtained from the 
plot of the fluorescence intensity ratio of I336.5/I334 versus lg 
c of Y-shaped copolymers. The CAC values of copolymers 
decreased from (6.53 ± 0.1) × 10−2 to (1.52 ± 0.1) × 10−3 g L−1, 
with an increase in length of P(LA-co-GA) (Table 2). This 
was because the increase in hydrophobic P(LA-co-GA) 
length enhanced the probability of polyester backbone wind-
ing and interaction among the polyester chains.
As shown in Figure 2, the obtained amphiphilic mPEG-
P(LA-co-GA)2 copolymers self-assembled into micellar or 
vesicular nanoparticles in PB at pH 7.4, depending on the 
length of hydrophobic P(LA-co-GA) moiety. The typical 
TEM micrographs of mPEG-P(LA12-co-GA9)2 micelles and 
mPEG-P(LA24-co-GA8)2 vesicles in PB at pH 7.4, 25°C, are 
shown in Figure 6A and C, respectively. The morphologies 
and homogeneous sizes of the nanoparticles were observed 
by TEM. In addition, nanoparticle sizes were quantitatively 
determined by DLS in PB at pH 7.4, 25°C, and they are shown 
in Figure 6B and D, as well as Table 2. The hydrodynamic 
radii (Rh) values of the nanoparticles decreased from 88 ± 2.5 
to 32 ± 3.2 nm as the length of P(LA-co-GA) increased, 
except for mPEG113-b-P(LA24-co-GA8)2, with an abnormal Rh 
of 144 ± 1.4 nm, attributed to its vesicular morphology.
In vitro DOX loading and release
DOX, an anthracycline anticancer drug, is one of the most 
common chemotherapeutic agents, known to have serious 
side effects, such as myelosuppression and cardiotoxicity. 
Formulation of DOX with nanocarriers through physical 
loading or chemical attachments into micellar/vesicular nano-
particles has been reported to improve the compatibility of 
DOX to normal tissues and enhance its therapeutic   efficacy.35 
In this study, DOX was chosen as a model anticancer drug 
and loaded into micellar and vesicular nanoparticles through 
a nanoprecipitation technique. Comparison of the drug-
loading abilities of the nanoparticles indicated that higher 
DLC and DLE were attributed to a longer hydrophobic 
P(LA-co-GA) block (Table 2). The values of DLC and DLE 
increased from 6.96 ± 0.2 to 10.34 ± 0.2 wt % and from 
41.76 ± 0.6 to 62.04 ± 0.4 wt %, respectively, as the length 
of the P(LA-co-GA) segment increased.
First, the DOX release behaviors of three micellar 
nanomedicines were studied in PB at pH 5.3, 6.8, and 7.4, 
37°C, for 336 hours; the results are shown in Figure 7A. 
The copolymer composition was found to be correlated 
to the drug release kinetics at all test pH levels, and the 
release rate decreased with the increase of P(LA-co-GA) 
content, which led to more compact nanomedicine core, 
thus decreasing the DOX release rate. Moreover, the in vitro 
DOX release behaviors of all the micellar/vesicular nano-
medicines were pH-  dependent. The release rate order was 
pH 5.3 . pH 6.8 . pH 7.4 (Figure 7), which corresponded 
to the pHs of late endosomes, tumor tissue, and the circula-
tory system, respectively.36 The accelerated DOX release at 
acidic pH can be attributed to the acid hydrolysis of ester 
bonds and the improvement of DOX solubility.37 In addi-
tion, it needs to be pointed out that all the nanomedicines 
displayed a relatively severe burst release in the current work, 
due to the weak interaction between P(LA-co-GA) and DOX. 
Fortunately, the burst drug release from the nanomedicines 
may be overcome by conjugating the drug molecules into 
nanoparticles through an acid-labile bond.38
It was more important to reveal DOX release from nano-
medicines in living cells. The cellular uptake and intracellular 
release behaviors of the nanomedicines toward the HeLa cells 
were evaluated by CLSM to determine whether the DOX 
released effectively in the intracellular environment. The HeLa 
cells were incubated with micellar and vesicular nanomedi-
cines, as well as free DOX (10 mg L−1 DOX), for 2 hours. 
As shown in Figure 8, the strength of the intracellular DOX 
fluorescence in the HeLa cells, observed after 2 hours incuba-
tion, was nearly the same in the nanomedicines and free DOX. 
Moreover, the strength of the intracellular DOX fluorescence 
decreased as the P(LA-co-GA) content increased, which was 
concordant with extracellular release behavior. It has been 
reported that the incorporation of DOX into the hydrophobic 
cores of nanoparticles decreases the DOX fluorescence inten-
sity compared with free DOX at the same concentration, due to 
Table 2 Properties of mPEG-P(LA-co-GA)2 nanoparticles
Copolymers CAC (10-3 g L-1) Rh (nm) DLC (wt %) DLE (wt %) IC50 (10-3 g L-1)
24 h 48 h 72 h
mPEG113-P(LA4-co-GA9)2 65.3 ± 1.0   88 ± 2.5   6.96 ± 0.2 41.76 ± 0.6 3.74 2.02 1.79
mPEG113-P(LA12-co-GA9)2 5.68 ± 0.2   78 ± 2.1   7.35 ± 0.3 44.10 ± 0.7 3.13 1.91 1.83
mPEG113-P(LA24-co-GA8)2 3.24 ± 0.1 144 ± 1.4   8.50 ± 0.2 51.00 ± 0.5 2.81 1.96 1.91
mPEG113-P(LA45-co-GA15)2 1.52 ± 0.1   32 ± 3.2 10.34 ± 0.2 62.04 ± 0.4 4.08 1.94 1.73
Abbreviations: mPEG, monomethoxy poly(ethylene glycol); P(LA-co-GA), poly(L-lactide-co-glycolide); CAC, critical aggregation concentration; Rh, hydrodynamic radius; 
DLC, drug loading content; DLE, drug loading efficiency; IC50, half maximal inhibitory concentration.
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the faster internalization of free DOX and the self-quenching 
effect of DOX in nanoparticles.8,35,39 Therefore, the enhanced 
fluorescence intensity in the HeLa cells incubated with 
micellar and vesicular nanomedicines should be the result of 
high endocytosis efficiency and improved intracellular DOX 
release from the nanomedicines.
In vitro cytotoxicities of nanoparticles 
and nanomedicines
MTT assays were used to estimate the in vitro cytotoxicities 
of nanoparticles and nanomedicines toward HeLa cells. As 
shown in Figure 9, the polyester nanoparticles showed no 
noticeable cytotoxicities up to 100 mg L−1, indicating their 
good biocompatibilities and displaying their potential as 
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Figure 6 Typical TEM micrographs of (A) mPEG-P(LA12-co-GA9)2 and (C) mPEG-P 
(LA24-co-GA8)2, and Rh of (B) (a) mPEG-P(LA4-co-GA9)2, (b) mPEG-P(LA12-co-GA9)2, 
and (c) mPEG-P(LA45-co-GA15)2, and (D) mPEG-P(LA24-co-GA8)2.
Abbreviations:  TEM,  transmission  electron  microscopy;  Rh,  hydrodynamic 
radius;  mPEG,  monomethoxy  poly(ethylene  glycol);  P(LA-co-GA),  poly(L-lactide- 
co-glycolide).
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Figure 7 release profiles of DOX from nanomedicines based on (A) (a1, a2, a3) 
mPEG-P(LA4-co-GA9)2, (b1, b2, b3) mPEG-P(LA12-co-GA9)2, and (c1, c2, c3) mPEG-
P(LA45-co-GA15)2 micelles at pH (a1, b1, c1) 5.3, (a2, b2, c2) 6.8, and (a3, b3, c3) 7.4; 
(B) mPEG-P(LA24-co-GA8)2 vesicles at pH (a) 5.3, (b) 6.8, and (c) 7.4 in PB at 37°C.
Note: Data are presented as mean ± SD (n = 3).
Abbreviations: DOX, doxorubicin; mPEG, monomethoxy poly(ethylene glycol); 
P(LA-co-GA),  poly(L-lactide-co-glycolide);  PB,  phosphate  buffer;  SD,  standard 
deviation.
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Figure 8 representative CLSM images of HeLa cells incubated with free DOX 
and nanomedicines for 2 hours: incubated with (A) free DOX and nanomedicines 
based  on  (B)  mPEG-P(LA4-co-GA9)2  micelle,  (C)  mPEG-P(LA12-co-GA9)2  micelle, 
(D)  mPEG-P(LA24-co-GA8)2  vesicle,  and  (E)  mPEG-P(LA45-co-GA15)2  micelle.  For 
each panel, the images from left to right show cell nuclei stained by DAPI (blue) and 
cellular DOX fluorescence (red), and overlays of the two images.
Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; DOX, doxorubicin; CLSM, 
confocal laser scanning microscopy; HeLa, Henrietta Lacks; mPEG, monomethoxy 
poly(ethylene glycol); P(LA-co-GA), poly(L-lactide-co-glycolide).
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2694
Li et alInternational Journal of Nanomedicine 2012:7
drug delivery vehicles. Furthermore, the cellular prolifera-
tion   inhibitions of nanomedicines against HeLa cells were 
estimated after incubation for 24, 48, and 72 hours, using free 
DOX as control. As shown in Figure 10, the nanomedicines 
displayed an effective inhibitory effect on the proliferation 
of HeLa cells for all the test times. The half maximal inhibi-
tory concentration (IC50) values are listed in Table 2. The IC50 
values of free DOX were 0.94, 0.48, and 0.44 mg L−1 at 24, 
48, and 72 hours, respectively, which were lower than those 
of the nanomedicines with equivalent DOX. The somewhat 
lower toxicities of the nanomedicines compared to free DOX 
were probably due to the gradual release of DOX within the 
cells. The ability not only to minimize drug loss in blood 
circulation, but also to selectively accumulate in tumor tis-
sue through EPR effects, may enhance its overall therapeutic 
efficacy in vivo relative to free DOX. In addition, with the 
prolongation of drug treatment time from 24 to 72 hours, 
the IC50 values of the nanomedicines decreased from ∼3 to 
∼1.8 mg L−1, quantificationally confirming that the nanomedi-
cines were more effective after lengthy treatment.
Characterization of in vitro hemocompatibilities of nano-
particles and nanomedicines was important, as they were 
designed to be administered via intravenous injection for 
most drug delivery applications. The blood compatibilities 
of the micellar/vesicular nanoparticles and nanomedicines 
were assessed by hemolysis assay on rabbit RBCs. The HR 
represents the amount of RBC membrane destroyed by sub-
stances in contact with RBCs, as smaller HR values repre-
sent better blood compatibility of biomaterials. RBCs were 
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(a) mPEG-P(LA4-co-GA9)2, (b) mPEG-P(LA12-co-GA9)2, (c) mPEG-P(LA24-co-GA8)2, and 
(d) mPEG-P(LA45-co-GA15)2 at (A) 24, (B) 48, and (C) 72 hours toward HeLa cells.
Note: Data are presented as mean ± SD (n = 6).
Abbreviations: DOX, doxorubicin; mPEG, monomethoxy poly(ethylene glycol); 
P(LA-co-GA),  poly(L-lactide-co-glycolide);  HeLa,  Henrietta  Lacks;  SD,  standard 
deviation.
co-incubated with nanoparticles, nanomedicines, and free 
DOX at different concentrations for 1 hour, and then the HR 
values were determined by spectrophotometer (Figure 11). 
As shown in Figure 11A, none of the nanoparticles showed 
conspicuous hemolytic activities on RBC, even at the very 
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high concentration of ∼0.5 g L−1, indicating great hemocom-
patible for potential biomedical application. In addition, the 
hemolytic activities of the nanomedicines were established 
with free DOX as control. As shown in Figure 11B, the 
nanomedicines were found to display less hemolysis activity 
toward RBCs compared with free DOX, indicating that the 
nanomedicines were hemocompatible, and thereby allow-
ing the potential clinical applications.
Conclusion
Four novel amphiphilic Y-shaped mPEG-P(LA-co-GA)2 
copolymers were prepared by alternating ROP of LA and 
GA monomers. The synthesized amphiphilic copolymers 
were substantiated to have exact chemical structure, control-
lable molecular weight, monodispersity, and amphiphilic 
properties. The copolymers formed into nanoscale   micellar/
vesicular aggregations with hydrophobic polyester cores 
and mPEG shells in PB at pH 7.4. Micellar/vesicular 
nanomedicines were fabricated by loading DOX into the 
compact nanoparticles. The in vitro release could be accel-
erated by decreasing P(LA-co-GA) length and mimicking 
tumor tissular and intracellular acidic conditions (pH 6.8 
and 5.3, respectively). The intracellular DOX release could 
be improved by shortening the hydrophobic P(LA-co-GA) 
block, and the nanomedicines displayed effective prolifera-
tion inhibition against HeLa cells at 24, 48, and 72 hours. 
The nanoparticles were hemocompatible, and the presence 
of copolymers in the nanomedicines reduced the hemolysis 
ratio (HR) of DOX significantly. These properties suggest that 
the novel DOX and amphiphilic, Y-shaped copolymer-based 
anticancer nanomedicines are attractive candidates as tumor 
tissular and intracellular targeting drug delivery platforms in 
vivo, with enhanced stability during circulation and acceler-
ated drug release at the target sites.
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